Stocks of FibroGen Inc (NASDAQ:FGEN) traded higher last session on Wall Street, up 7.48% to $1.58.
FGEN stock price is now -20.95% away from the 50-day moving average and -8.22% away from the 200-day moving average. The market capitalization of the company currently stands at $156.06M.
With the price target reduced from $4 to $2, BofA Securities Downgraded its rating from Neutral to Underperform for FibroGen Inc (NASDAQ: FGEN). , while ‘Stifel’ rates the stock as ‘Hold’
In other news, Wettig Thane, CEO bought 50,000 shares of the company’s stock on Mar 07 ’24. The stock was bought for $95,470 at an average price of $1.91. Upon completion of the transaction, the CEO now directly owns 470,178 shares in the company, valued at $0.74 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 01 ’23, Director Henderson Jeffrey William sold 2,000 shares of the business’s stock. A total of $2,060 was realized by selling the stock at an average price of $1.03. This leaves the insider owning 28,866 shares of the company worth $45608.28. A total of 7.02% of the company’s stock is owned by insiders.
During the past 12 months, FibroGen Inc has had a low of $0.33 and a high of $20.90. The fifty day moving average price for FGEN is $1.9987 and a two-hundred day moving average price translates $1.7215 for the stock.
The latest earnings results from FibroGen Inc (NASDAQ: FGEN) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.57, missing analysts’ expectations of -$0.42 by -0.15. This compares to -$0.70 EPS in the same period last year. The net profit margin was -192.37% and return on equity was -42790.17% for FGEN. The company reported revenue of $27.14 million for the quarter, compared to $34.37 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -21.03 percent. For the current quarter, analysts expect FGEN to generate $36.67M in revenue.
